RedHill Biopharma Ltd.RDHLNASDAQ
Loading
R&D Expense Growth TrendStable
Percentile Rank41
Year-over-Year Change
Year-over-year research & development expense growth
Latest
0.00%
↑ 100% vs avg
Percentile
P41
Within normal range
Streak
1 qtr
Consecutive declineStable
Average
-1.41%
Historical baseline
| Period | Value |
|---|---|
| Q2 2025 | 0.00% |
| Q1 2025 | 3.77% |
| Q4 2024 | 0.00% |
| Q3 2024 | 40.97% |
| Q2 2024 | 0.00% |
| Q1 2024 | -44.95% |
| Q4 2023 | 0.00% |
| Q3 2023 | -52.00% |
| Q2 2023 | 15.04% |
| Q1 2023 | -4.32% |
| Q4 2022 | -29.71% |
| Q3 2022 | 9.51% |
| Q2 2022 | -51.93% |
| Q1 2022 | -47.82% |
| Q4 2021 | 0.86% |
| Q3 2021 | -43.67% |
| Q2 2021 | 38.00% |
| Q1 2021 | 20.92% |
| Q4 2020 | 43.16% |
| Q3 2020 | 34.51% |
| Q2 2020 | 16.24% |
| Q1 2020 | 21.49% |
| Q4 2019 | -18.69% |
| Q3 2019 | -59.85% |
| Q2 2019 | 29.78% |
| Q1 2019 | -7.03% |
| Q4 2018 | -12.77% |
| Q3 2018 | 9.60% |
| Q2 2018 | -5.80% |
| Q1 2018 | -22.62% |
| Q4 2017 | 2.29% |
| Q3 2017 | -3.89% |
| Q2 2017 | 3.65% |
| Q1 2017 | 8.55% |
| Q4 2016 | 6.51% |
| Q3 2016 | 16.70% |
| Q2 2016 | 28.98% |
| Q1 2016 | -5.55% |
| Q4 2015 | 26.92% |
| Q3 2015 | -23.36% |